im looking for data on the use of lenalidomide in Multiple Myeloma patients in actual clinical practice. If the data is audit data thats fine too. Im happy to work with anyone for publication on this (im a medical statistician)
thanks
ifty
Lenalidomine present good response associated with Bortezomib and it is a new class of inhibitor of angiogenesis With less than side effects of thalidomide. Looking for paper in blood or New England of the international myeloma foundation. Best wishes. Luiz
I think your man is Dr. Jesus San Miguel at the Hematology Department of the Clinica Universitaria de Navarra, Pamplona, Spain.
He has ample experience in clinical trials in multiple myeloma (you can search him in PubMed) with many different drugs. If you contact him I think he could help you.
Dear Ifty
In our hands, Len/dex gives 52% OS at 3 years (number of patients 160) in 2nd line, 44% in 3rd line (126), 32% in 4th line (95), 35% in 5th line (95), 10% in 6th (34) and 10% in 7th (17).
Dear Hareth: Thanks for this ver useful information. What is is the median OS and PFS in each case ? Median OS seems close to 3 years
Would you be prepared to work with me on the data to derive estimates of QALYs? - or do you have these ?
Bw
Ifty